Comparative anesthetic efficacy evaluation of 2 percent Lignocaine, 3 percent Prilocaine and 4 percent Articaine during pulpectomy in mandibular primary molars - A parallel randomized control trail. - NIL

Start Date31 Mar 2025

Sponsor / Collaborator-

CTRI/2025/03/082115

/ Not yet recruitingPhase 3IIT

Effectiveness of CCLAD, Low Level Laser, Precooling AND Topical Anesthetic in Reducing Pain During Palatal Anesthesia - NIL

Start Date21 Mar 2025

Sponsor / Collaborator-

NCT06703580

/ RecruitingPhase 3IIT

Intrathecal Hyperbaric Prilocaine in Adult Patients Undergoing Knee Arthroscopy, a Randomized Controlled Trail

The goal of this randomised trial is to use a short acting local anaesthetic drug (hyperbaric prilocaine 2%) which is beneficial in short operations which are performed as a day case surgery.
in this study the investigators will use 3 different doses of prilocaine 2% (40,50 or 60 mg ) intrathecal (in spinal anaesthesia) in participants undergoing arthroscopy on the knee.
the primary outcome is to compare time to micturate (go to the bathroom) between the three groups .
the secondary outcomes are:
* time to recovery of the motor and sensory block
* time to discharge from post anesthesia care unit
* any complications ; itching, lowered blood pressure, nausea and vomiting.

Start Date30 Nov 2024

Sponsor / Collaborator

Cairo University

100 Clinical Results associated with Prilocaine Hydrochloride

100 Translational Medicine associated with Prilocaine Hydrochloride

100 Patents (Medical) associated with Prilocaine Hydrochloride

2,489

Literatures (Medical) associated with Prilocaine Hydrochloride

01 Jun 2025·BJA Open

The ED95 of lidocaine and prilocaine for ultrasound-guided brachial plexus blocks for surgical anaesthesia: a randomised controlled clinical trial

Article

Author: Zohar, Sarah ; Hopkins, Philip M ; Vats, Anurag ; Gupta, Pawan K ; Berrill, Andrew

BackgroundOur trial addresses the gaps in the current literature by directly estimating the ED₉₅ of short-acting local anaesthetics for ultrasound-guided axillary and supraclavicular brachial plexus blocks for surgical anaesthesia.MethodsFour double-blind prospective studies were organized in two separate arms. Patients were randomised between studies A (lidocaine 1% with adrenaline) and B (lidocaine 2% with adrenaline) for axillary blocks and between studies C (prilocaine 1%) and D (lidocaine 1% with adrenaline) for supraclavicular blocks. All statistical modelling and analysis were performed using the modified continual reassessment method. The primary endpoint of the studies was the loss of cold and pin-prick sensations in the sensory distributions of the median, musculocutaneous, radial, and ulnar nerves.ResultsFor axillary blocks, the estimated ED₉₅ of lidocaine 1% with adrenaline was 40 ml (95% credibility interval: 89.5-99.2%), and lidocaine 2% with adrenaline was 15 ml (95% credibility interval: 87.4-97.5%) (studies A and B: 41 and 40 patients, respectively). The ED₉₅ could not be determined for supraclavicular blocks as it fell outside the dose range considered in the studies (studies C and D: 31 and 42 patients, respectively).ConclusionsWe achieved a 95% success rate for axillary blocks using lidocaine (1% and 2%) with adrenaline within our dosing limits. For supraclavicular blocks, >40 ml of prilocaine 1% or lidocaine 1% with adrenaline may be required to consistently achieve a 95% success rate. Our studies highlight the continual reassessment method as a credible methodology for dose-finding studies in regional anaesthesia.Clinical trial registrationEudraCT ref: 2010-018466-22.

03 May 2025·Analytical Letters

Determination of Sedative and Anesthetic Drug Residues in Aquatic Food Products Using Solid Phase Extraction (SPE) and Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)

Author: Xin, Lina ; Xia, Ning ; Li, Minglu ; Chen, Yun ; Wang, Li ; Liang, Feiyan

The residues of sedative and anesthetic drugs in aquatic products are an important factor affecting food safety.In order to screen the residues of sedative and anesthesia drugs in aquatic products, a rapid and sensitive method was established using solid phase extraction (SPE) and high-performance liquid chromatog.-tandem mass spectrometry (HPLC-MS/MS).The samples were extracted by 80% aqueous acetonitrile by an alumina column and separated by a C18 column.The mass spectra were determined in pos. ion mode.The standard curves were matrix matched and quantified by the external standard method.The results showed that the linear ranges of the drugs in aquatic products were from 0.5 to 100 μg kg-1.The correlation coefficient (R2) was greater than 0.990 and the detection limits were between 0.001 and 0.322 μg kg-1.The average recovery rate and relative standard deviation were between 78.64% and 112.15% and from 0.41%-8.26%.Overall, the developed method showed promising results for the simultaneous qual. and quant. determination of the drug residues in aquatic products.

01 Apr 2025·Canadian Journal of Anesthesia/Journal canadien d'anesthésie

Optimal local anesthetic for spinal anesthesia in patients undergoing ambulatory non-arthroplasty surgery: a systematic review and Bayesian network meta-analysis of randomized controlled trials

Review

Author: Guffey, Ryan ; Singh, Preet M ; Siddiqui, Naveed T ; Singh, Narinder P ; Makkar, Jeetinder K

PURPOSEDosing and types of local anesthetic agents for spinal anesthesia in ambulatory settings vary significantly. We sought to conduct a network meta-analysis to evaluate the effect of the type and dose of local anesthetic on outcomes in patients undergoing ambulatory surgery.METHODSAfter PROSPERO registration (CRD42023399356), we searched various databases for randomized controlled trials (RCTs) evaluating adult patients undergoing daycare surgery under spinal anesthesia. Most included trials focused on patients undergoing knee arthroscopy, while other covered procedures were perineal, lower abdominal, and limb surgeries. Unfortunately, we could not include trials on arthroplasty surgery owing to the lack of RCTs in this area. We used Confidence in Network Meta-Analysis (CINeMA) to assess the confidence in the estimates, and we used surface under the cumulative ranking curve (SUCRA) to determine the probability rank order. The primary outcome was the time to discharge. Intraoperative effectiveness of anesthetic, sensory, and motor blockade duration; time to first micturition; time to ambulation; and adverse effects such as urinary retention and transient neurologic symptoms (TNS) were the secondary outcomes.RESULTSOverall, this study included 44 trials comprising 3,299 patients, each comprising 11 distinct agents (2-chloroprocaine, articaine, high-dose bupivacaine, low-dose bupivacaine, lidocaine, high-dose levobupivacaine, low-dose levobupivacaine, mepivacaine, prilocaine, high-dose ropivacaine, and low-dose ropivacaine). Low- to moderate-certainty evidence showed that 2-chloroprocaine, lidocaine, and mepivacaine were superior for discharge readiness, while 2-chloroprocaine ranked highest for other outcomes (sensory and motor block duration, time to first ambulation, and spontaneous voiding).CONCLUSIONSEvidence supports 2-chloroprocaine for short-duration spinal anesthesia in the ambulatory setting.STUDY REGISTRATIONPROSPERO ( CRD42023399356 ); first submitted 13 February 2023.

News (Medical) associated with Prilocaine Hydrochloride

07 Nov 2023

·www.prnewswire.com

Advanced Anesthesia Devices and Ambulatory Surgical Centers Propel Growth in the US Anesthesia Market

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market (by segment, Type, Drug Product, & Device Product): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market is poised for significant growth, with a projected value of US$6.83 billion in 2023, experiencing a robust CAGR of 6.78% during the forecasted period. Anesthesia, the use of drugs to alleviate pain during medical procedures, is essential in the healthcare industry and is administered through various means such as injection, inhalation, topical application, and more. Market Segmentation The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices. Among these segments, anesthesia drugs currently hold the majority share, while the anesthesia devices segment is expected to experience substantial growth due to increased healthcare expenditure in the region. Types and Products In terms of types, the US anesthesia drugs market is categorized into General, Local, and other anesthesia. The General anesthesia drug segment dominates the market, followed by local anesthesia drugs. The development of novel anesthesia drugs through pharmaceutical R&D is expected to create growth opportunities in the "other anesthesia drugs" segment. When considering device products, the market is segmented into advanced, basic, and integrated anesthesia devices. The advanced segment holds the largest share in the market, followed by integrated anesthesia devices. Ongoing advancements in anesthesia monitoring devices and the demand for improved monitoring contribute to the growth of the advanced anesthesia monitoring devices market. The market is further categorized by drug product into Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine, and other local anesthetics. Lidocaine anesthesia drugs have the highest market share, followed by Bupivacaine and Ropivacaine. The market is anticipated to grow due to increasing patient populations and a rise in medical and surgical procedures. Key Drivers and Challenges Driver: Increase in Monitored Anesthesia Use The adoption of Monitored Anesthesia Care (MAC) is on the rise. MAC involves specific anesthesia services for procedures performed under local anesthesia with sedation and analgesia, allowing patients to maintain consciousness. Patients are opting for monitored anesthesia to ensure satisfaction during surgeries, leading to increased usage of anesthesia equipment and drugs. Challenge: Side Effects of Anesthesia While anesthesia is generally administered by anesthesiologists, it can sometimes lead to side effects, including nausea, headache, vomiting, and shivering, among others. General anesthetics can affect the central nervous system, causing drowsiness and coordination problems. These side effects can deter some patients and impact the growth of the anesthesiology market. Trend: Growth of Ambulatory Surgical Centers (ASC) The establishment of ambulatory surgical centers (ASCs) is escalating due to an aging population and the prevalence of chronic diseases. ASCs offer improved reimbursement and a reduced risk of healthcare-associated infections, attracting more patients. This growth in ASCs is driving the demand for anesthesia drugs and devices. COVID-19 Analysis The COVID-19 pandemic led to increased utilization of intensive care unit (ICU) ventilators and anesthesia machines for longer-term ventilation. Anesthesia drugs were used during longer-term ventilation with anesthesia machines. Initially, anesthesia drug demand decreased in 2020 due to postponed or canceled surgeries. However, as elective surgeries resumed, anesthesia drug consumption increased. Key Players The US anesthesia drugs and devices market is competitive and features several major players, including Baxter International Inc., Envision Healthcare Corporation (KKR & Co. Inc.), Becton, Dickinson and Company, TeamHealth (Blackstone), Teleflex Incorporated, Dragerwerk AG & Co. KGaA, B. Braun Avitum AG (Braun), 3M Company, Abbvie Inc., AstraZeneca Plc, Abbott Laboratories, ICU Medical, Inc., SunMed LLC, and General Electric Company. Top Impacting Factors Growth Drivers Rising Geriatric Population Growing Healthcare Expenditure Increase in Monitored Anesthesia Use Increase In Number Of Approval For Anesthesia Drugs Challenges Side Effects of Anesthesia Lack of Skilled Anesthesiologist Trends Escalating Establishment of Ambulatory Surgical Centers (ASC) Technological Enhancement of Anesthesia Devices For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

18 Nov 2022

·www.prnewswire.com

US Anesthesia Drugs and Devices Market to Reach $8.88 Billion by 2027

DUBLIN, Nov. 18, 2022 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market: Analysis By segment, By Type, By Drug product, By Device Product, Size And Trends With Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market in 2021 was valued at US$5.99 billion. The market value is predicted to reach US$8.88 billion by 2027. Anesthesia is the use of medicines to prevent pain during surgery and other procedures. They may be given by injection, inhalation, topical lotion, spray, eye drops, or skin patch. Anesthesia can cause one to have a loss of feeling or awareness. The market is expected to grow at a CAGR of 6.80% during the forecast period of 2022-2027. Due to increasing number of surgeries, aging population with increasing chronic conditions, and advancements in anesthesia technologies, the market for anesthesia drugs and devices would grow in the years to come. Market Segmentation Analysis: By Segment: The report provides the bifurcation of the market into two categories based on the segment: anesthesia drugs and anesthesia devices. In 2021, anesthesia drugs segment held a major share of more than 55% in the market. On the other hand, the anesthesia devices segment is expected to grow at a significant CAGR in the forthcoming years owing to the rising healthcare expenditure in the region. By Type: On the basis of type, the US anesthesia drugs market is divided into three types namely general, local and other anesthesia. In 2021, general anesthesia drug segment held a major share of more than 39% in the market. This was being followed by local anesthesia drugs. R&D activities in the pharmaceutical industry to formulate novel anesthesia drug is expected to provide remunerative opportunities for expansion of the US other anesthesia drugs market during forecast period. By Device Product: The report provides the bifurcation of the market into three segments based on the device product: advanced, basic and integrated. In 2021, advanced segment held a major share of 62% in the market. This was being followed by integrated anesthesia device. The constant development in the field of the anesthesia monitoring devices and high demand for the better monitoring devices are also anticipated to push the growth in the US advanced anesthesia monitoring devices market. By Drug Product: The report provides the bifurcation of the market into seven segments based on the drug product: Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine and Other Local Anesthetics. In 2021, Lidocaine anesthesia drug segment held a major share of 32% in the market. This was being followed by Bupivacaine, Ropivacaine. The market is anticipated to propel during forecasted years owing to the expanding patient population and the rise in medical and surgical procedures. Market Dynamics: Growth Drivers: One of the most important factors impacting the US anesthesia drugs and devices market is rising geriatric population. Steady growth in aging population raised the incidence of the chronic condition over the past decade. This had caused increasing number of surgical procedures of elderly patients. Additionally, benefits such as advances in surgery and anesthesia can improve function and quality of life for older patients also supported market growth. Thus, the positive acceleration in aging population consequently supported the growth of the anesthesia drugs and devices market in the US. Furthermore, the market has been growing over the past few years, due to factors such as growing healthcare expenditure, increase in monitored anesthesia use, increase in number of approval for anesthesia drugs and many other factors. Challenges: However, the market has been confronted with some challenges specifically, lack of skilled anesthesiologist, etc. - Trends: The market is projected to grow at a fast pace during the forecast period, due to various latest trends such as the escalating establishment of ambulatory surgical centers (ASC), technological enhancement of anesthesia devices, etc. Technology upgradation such as Closed loop TIVA and Ultrasound-Guided Regional Anesthesia (UGRA) are expected to propel the US drug and devices market during forecasted years. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Impact of COVID-19 5. Market Dynamics 6. Competitive Landscape 7. Company Profiles Companies Mentioned KKR & Co. Inc. (Envision Healthcare Corporation) Baxter International Inc. Blackstone (TeamHealth) Becton, Dickinson and Company Braun (B. Braun Avitum AG) 3M Company Abbvie Inc. Teleflex Incorporated Dragerwerk AG & Co. KGaA AstraZeneca Plc Abbott Laboratories General Electric Company ICU Medical, Inc SunMed LLC For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

14 Sep 2017

·www.biospace.com

AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal

September 14, 2017 By Alex Keown , BioSpace.com Breaking News Staff LONDON – AstraZeneca struck a deal with South Africa-based Aspen Global Incorporated to divest the remaining rights to a portfolio of anesthetics for up to $766 million. Aspen gained the U.S. rights to the drug portfolio in the latest deal. The deal comes about 14 months after Aspen acquired the non-U.S. rights to the same portfolio of drugs. That deal was also lucrative for AstraZeneca. Aspen paid up to $770 million for the non-U.S. rights, when milestones are factored in. Aspen now has global rights to the anesthetic portfolio that includes Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest, AstraZeneca said. Under terms of the new deal, Aspen will acquire the remaining rights to the intellectual property and manufacturing know-how related to the anesthetic medicines for an upfront consideration of $555 million. Aspen will pay an additional $211 million in performance-related milestones through Nov. 30 2019. AstraZeneca will continue to manufacture and supply the medicines to AGI during a transition period of up to five years. Aspen’s acquisition has been profitable for the company, Stephen Saad , Aspen’s chief executive officer, said in a statement. The deal is expected to close in the fourth quarter of this year. It is not expected to impact AstraZeneca’s financial guidance. Mark Mallon , head of AstraZeneca’s portfolio strategy, said Aspen and his company have both benefitted from the commercial agreement first struck in 2016. “As our relationship has evolved, AGI has shown that it is in a strong position to maximize the value and reach of the anesthetic medicines through its extensive commercial network. Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas,” Mallon said in a statement. AstraZeneca has positioned itself to have a three-pillar focus – oncology, cardiovascular and metabolic disease treatments, as well as respiratory diseases, which was boosted by the $575 million acquisition of Takeda Pharmaceutical Company ’s core respiratory business. In August, the company delved deeper into developing respiratory treatments through a $30 million partnership with Germany-based Ethris GmbH , a mRNA specialist. The deal will see MedImmune , the biologics research division of AstraZeneca , collaborate on mRNA therapeutics targeting pulmonary problems, such as asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. The two teams will develop the pulmonary treatments using Ethris’ proprietary SNIM RNA technology. In July, AstraZeneca’s oncology arm received a substantial boost after it inked a deal with Merck to use AstraZeneca’s PARP inhibitor Lynparza in combination with PD-1 inhibitors developed by both companies . Lynparza, which has been approved in the United States for the treatment of one type of ovarian cancer, will be combined with AstraZeneca’s Imfrinzi and Merck’s Keytruda. In March, AstraZeneca announced that Lynparza delayed the recurrence of ovarian cancer by more than two years compared to placebo in a Phase III study. AstraZeneca is looking for new revenue streams as it faces challenges from generic drugs. Earlier this year, the company said revenue will likely decline in 2017 due to those generic challenges, particularly as generic drugs eat into the marketshare of its blockbuster anti-cholesterol drug Crestor. Earlier this year, AstraZeneca laid out how many of its drugs are losing revenue due to competition. For example, AstraZeneca said sales of schizophrenia drug Seroquel XR were down 83 percent in the United States and 37 percent in Europe. COPD drug Symbicort saw a decline of 21 percent in the United States, which AstraZeneca said was in line with predictions for 2017.

Phase 3AcquisitionDrug Approval

100 Deals associated with Prilocaine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01243	Prilocaine Hydrochloride	N01BB04	DB00750

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperemesis Gravidarum	China	Hubei Jumpcan Pharmaceutical Co., Ltd.	13 Feb 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AUA2024	Not Applicable	Premature Ejaculation	-	Dapoxetine 30 mg+mirodenafil 50 mg	(eplwhtyfdv) = rzzxcnpmyl vgypbehgaq (wzhlggvgxm, 23.0 - 400.0)	Positive	01 May 2024
				OLNP-05	(eplwhtyfdv) = nfzsobdbly vgypbehgaq (wzhlggvgxm, 140.0 - 410.0)
NCT02973048 (not provided, CTgov)	Phase 3	Pain \| Hypotension	40	Hyperbaric bupivacaine (Hyperbaric Bupivacaine)	lcaeursdof(yeevcnmhdm) = bbufitjvwg badohbhgwl (xalzekosmg, bftsltenvi - jgszyplwxu) View more	-	02 Jul 2020
				Hyperbaric prilocaine (Hyperbaric Prilocaine)	lcaeursdof(yeevcnmhdm) = tkyegdqkea badohbhgwl (xalzekosmg, lmssidmyqa - eofqxlqxbk) View more
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	sbqjnqjaue(eilykwvzcq) = jvafhzjdlh kjgoldefmw (cepgqoiqpk, ialmrtujbc - yutftrodjh) View more	-	16 May 2019
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	sbqjnqjaue(eilykwvzcq) = gopfvwwypl kjgoldefmw (cepgqoiqpk, ktggkspcqt - dbiwxmxfoi) View more
NCT05834647 (Pubmed \| Local Reg Anesth)	Phase 4	Anesthesia	-	Prilocaine hydrochloride 2% hyperbaric solution	hdgbwjinyb(druzzookyb) = qnxrbfdqid lpbqobhord (cmehfjlcgy ) View more	-	01 Jan 2017
NCT00556478 (CTgov)	Phase 2/3	Premature Ejaculation	256	prilocaine+PSD502, contains a mixture of lidocaine (Double-Blind Active)	vtymyrjxrl(grodrmlmdr) = uauuzoxmkt fcsgtqctdj (rwynjwzlvq, vqbmjuvqgo - pwhzpphdoe) View more	-	26 Sep 2016
				Placebo (Double-Blind Placebo)	vtymyrjxrl(grodrmlmdr) = alnfemsmnc fcsgtqctdj (rwynjwzlvq, emdyjvjoxx - umwsyjbgfz) View more
NCT02336958 (CTgov)	Not Applicable	Carotid Stenosis	40	intermediate cervical plexus block ropivacaine+jugular infiltration prilocaine (Ropivacaine)	nmtkejcncv(zwttklgbln) = wglsjtpnmt ayuqrhyhkx (cezyptfnlc, bgfshomjrw - guhfjqpqtt) View more	-	23 Mar 2015
				pericarotidal infiltration (placebo comparator) saline+intermediate cervical plexus block ropivacaine+jugular infiltration prilocaine (Saline)	nmtkejcncv(zwttklgbln) = lfwbahqlvp ayuqrhyhkx (cezyptfnlc, gfnmktnwfz - ormotzdkof) View more
NCT01643616 (CTgov)	Not Applicable	-	250	ultrasound guidance+Prilocaine 1%+Ropivacaine 0.75%+midazolam (Group US)	zssztiqpal(jqukjybsrx) = phavrvvliz xknlcitifc (jduavgslll, fmeddvvkfw - zcxsitpbjy) View more	-	01 Nov 2013
				nerve stimulation technique+Prilocaine 1%+Ropivacaine 0.75%+midazolam (Group NS)	zssztiqpal(jqukjybsrx) = fmmahdotpn xknlcitifc (jduavgslll, gvsiwanjmy - pwoevvdomx) View more
NCT01309360 (CTgov)	Phase 4	-	120	prilocaine 1%+midazolam (Group A : 40ml Prilocaine 1%)	ipxslmkgfm(bxshvvbzsq) = eraqnszerb dqnzxeuqax (fmwehfqprq, kocsallhbp - nermznweki) View more	-	27 Jun 2011
				prilocaine 1%+midazolam (Group B : 30ml Prilocaine 1%)	ipxslmkgfm(bxshvvbzsq) = dytbcquvnb dqnzxeuqax (fmwehfqprq, xscocnyuol - wemmsnvtqf) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Prilocaine Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation